Efficacy of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer patients
Objective To explore the efficacy and safety of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer(NSCLC)patients.Methods This prospective,single-arm clinical study included twenty-five patients with locally advanced NSCLC from January 2020 to March 2021 who received durvalumab combined with cisplatin and docetaxel neoadjuvant therapy for 2 cycles before surgery.Then they received durvalumab monotherapy or combined with cisplatin and docetaxel adjuvant therapy after surgery.After discharge,patients were followed up every 1 to 2 months for the first six months and every 3 to 6 months thereafter.The primary outcome was pathological remission rate.Secondary outcome measures were clinical response rate,disease-free survival(DFS),and overall survival(OS).Results The mean age of all enrolled patients was(59.84±7.14)years,including 18 males(72.00％)and 7 females(28.00％).The primary outcome indicated that 56％patients achieved significant pathological response,among which 24％achieved complete pathological response.The secondary outcome showed that 0,60％,36％and 4％patients achieved clinical complete response,partial response,disease stability and disease progression,and the overall objective response rate was 60％.The 1-year DFS was 79％,and the 1-year OS was 90％.There was no correlation of Eastern Cooperative Oncology Group performance status and TNM stage with DFS or OS.Besides,The most common adverse events were alopecia(48％),fatigue(40％),nausea and vomiting(36％).Most of the adverse events were at grade 1 to 2,only a few were at grade 3 to 4.Conclusion Durvalumab combined with cisplatin and docetaxel exhibits good efficacy profile as neoadjuvant therapy in locally advanced NSCLC patients.
durvalumabcisplatin and docetaxelneoadjuvant therapylocally advanced non-small cell lung cancerefficacysafety
NETL
NSTL
万方数据
